News

Important Class Action Update for Sage Therapeutics Investors

Important Class Action Update for Sage Therapeutics Investors

Important Information for Sage Therapeutics Investors

Are you an investor in Sage Therapeutics, Inc. (NASDAQ: SAGE) who has experienced significant losses? If so, it’s crucial that you pay attention to the upcoming October 28 deadline. A securities class action has been initiated that might provide you with an opportunity for compensation without incurring out-of-pocket expenses.

Why You Should Consider Legal Counsel

The Rosen Law Firm, a respected name in investor rights, is reminding all investors who purchased Sage securities between April 12, 2021, and July 23, 2024, of the importance of securing counsel. Being part of this class action could facilitate compensation for your losses, and the firm emphasizes that this can be achieved with a contingency fee arrangement.

What Steps Should You Take?

To participate in the Sage class action lawsuit, it is advisable to reach out directly to the Rosen Law Firm. Potential claimants can contact Phillip Kim, Esq., toll-free at 866-767-3653 or email the firm for more information. This is an essential step for those who would like to act before the deadline.

The Case Details Explained

There are significant allegations surrounding Pragmatic Therapeutics. The multinational law firm claims that during the class period, the firm made numerous false statements and did not disclose critical information regarding its products. These misleading statements primarily revolved around the efficacy of their leading drugs such as zuranolone, SAGE-718, and SAGE-324.

What Were the Allegations?

The lawsuit asserts that Sage Therapeutics overstated the effectiveness of its drugs used to treat conditions like postpartum depression and major depressive disorder. More precisely, it alleges that the FDA is unlikely to approve their new drug application (NDA) for these treatments, contradicting the public statements made by the company.

The Importance of Selecting Experienced Counsel

Securities class actions can be complex and lengthy. Investors are advised to choose a law firm with a strong history in this field. The Rosen Law Firm has achieved notable success in numerous securities class actions, which emphasizes the importance of expert legal representation in ensuring that your interests are effectively advocated.

Why Choose the Rosen Law Firm?

Investors are encouraged to consider firms with a proven track record in litigating securities class actions. In 2019, for instance, the firm recovered over $438 million for its clients. Their reputation for excellence has been recognized multiple times, having ranked No. 1 for class action settlements against companies in prior years.

How Can You Stay Updated?

For updates, it's possible to follow the Rosen Law Firm on social media platforms, including LinkedIn, Twitter, and Facebook. This ensures that investors are kept informed on the developments of the case and can stay connected with other stakeholders.

Frequently Asked Questions

What is the significance of the October 28 deadline?

The deadline is crucial for investors who wish to be part of the class action and potentially seek compensation for their losses.

How can I join the Sage Therapeutics class action?

You can contact the Rosen Law Firm directly via phone or email to express your interest in joining the class action.

What are the potential outcomes of this lawsuit?

If successful, the lawsuit could result in compensation for investors who have suffered financial losses during the specified class period.

When will the court decide on the class status?

The court will determine whether to certify the class after evaluating the case, and this process can take time.

Do I need to hire a lawyer now, or can I wait?

You can remain an absent class member, but hiring a lawyer may strengthen your case and ensure you understand your rights effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hugel's Sales Climb Despite Changes in Sales Models

Updated Category News Views 97

Hugel's Financial Fortunes in a Shifting Landscape Who would've thought? That’s the vibe hugging the numbers Hugel Inc. just dropped. Their performance for the first three quarters of 2026 is in the books, and results show consolidated net sales climbing 15% year-on-year. Just how did they pull this rabbit out of the hat? Let's dissect this a bit. Cracking the Code of...

Continue Reading
Are BWIN, LFCR, PCRX Shareholder Deals Fair?

Updated Category News Views 100

What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...

Continue Reading
MRP Securities Fraud: Investors Eye Millrose Case

Updated Category News Views 104

Millrose's Troubles: A Closer Look at the Fraud Accusation Now, here's a pickle. Millrose Properties, Inc. (NYSE: MRP) has landed itself in hot water. We've got a bona fide class action lawsuit on our hands, and Schall, Brown & Schwartz LLP is waving the flag, rallying investors to step up and face the music. Turns out the company's talk might not have walked the walk...

Continue Reading
Peabody's Q3 2026: Margins Climb Despite Net Loss

Updated Category News Views 0

Tough Quarters but Promising Margins Alright, Peabody's Q3 2026 isn't the most sunshine-filled report I've laid eyes on, but it's not all shadows either. Sure, they posted a net loss of $32.8 million, better than last year's $70.1 million drain. Admit it or not, that's improvement. And yet, the real gem here is those expanding margins gleaming despite the loss-heavy...

Continue Reading
Omnissa Expands AI Sovereignty: New Markets, New Control

Updated Category News Views 41

Omnissa Rolls Out AI Sovereignty Across New Markets In the world of AI, where data is king and control is the crown, Omnissa is making bold moves with its latest expansion announcement. The company's Sovereign Solution (OSS) is now reaching into six fresh markets across Europe and Asia, offering organizations a vital grip on their digital domains like never before. Talk...

Continue Reading
UN Forum Unleashes LatAm CEO Coalition for Action

Updated Category News Views 89

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Continue Reading
Lincoln Index Highlights Growth, But Risks Linger

Updated Category News Views 130

Private Market Dynamics: A Mixed Bag in Q3 The Lincoln Private Market Index (LPMI) is giving us quite the mixed message this quarter. Up by 2.8%, the index is applauding earnings growth in private companies. Not too shabby, right? Yet, let's not pop the champagne just yet. It's not all sunshine and roses—credit risk clouds are looming large. Steady Performers, but Not...

Continue Reading
Lumentum Holders Question Marvell Deal Fairness: Legal Eyes

Updated Category News Views 82

What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...

Continue Reading
Fluence Energy Faces Legal Trouble: A Closer Look

Updated Category News Views 31

Fluence Energy's Legal Tangle: What It Means for Investors You ever get that gut punch feeling when a company you’re watching stumbles? Well, Fluence Energy, Inc. (NASDAQ: FLNC) seems to have handed that to its shareholders lately. There's a class action lawsuit out there that’s got investors not only scratching their heads but also reaching for their phones. The...

Continue Reading
EXPO 2027 Belgrade: Serbia's Tourism Game-Changer?

Updated Category News Views 104

An Unexpected Stage: Belgrade's Big Show Well, who's betting on Belgrade making waves in the global travel scene? EXPO 2027 is shaping up to do just that, and it’s taking the scenic route. Serbia, a country not always on the grand tourist itineraries, could finally hog the spotlight come 2027. Under the banner of 'Play for Humanity: Sport and Music for All,' they're...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Latest Trends in Alcohol Policy and Health Advances

Updated Category News Views 436

Exploring the Latest Trends in Alcohol Policy and Health Advances Alcohol Justice has unveiled its February 2025 eNews, delivering a thorough overview of significant news, research, and advocacy surrounding the effects of alcohol on communities and public health. This month’s publication emphasizes vital advancements in the sphere of alcohol policy, paying close...

Continue Reading
Explore the Exciting New Manor Collection at Sereno Canyon

Updated Category News Views 273

Announcing the Grand Opening of the Manor Collection Exciting news is on the horizon as Toll Brothers, Inc. (NYSE:TOL), the nation’s leading luxury home builder, proudly presents the grand opening of its new Manor Collection at Sereno Canyon. This exceptional community is nestled in the breathtaking landscape of Scottsdale and offers residents a blend of luxury,...

Continue Reading
Federal Home Loan Bank of Boston Reports Strong Financial Results

Updated Category News Views 170

Federal Home Loan Bank of Boston Reports 2024 Results The Federal Home Loan Bank of Boston declared its preliminary financial results for the fourth quarter and the year 2024. The Bank reported a significant net income of $82.1 million for the last quarter of 2024, contributing to an impressive annual total of $290.5 million. These results are expected to be highlighted...

Continue Reading
Understanding the Rising Short Interest in IBM Stock

Updated Category News Views 133

Understanding the Rising Short Interest in IBM Stock IBM's short interest has significantly increased, recently rising by 12.5%. Currently, there are 23.16 million shares that have been sold short, representing 2.52% of the total shares available for trading. With this level of short interest, it would take traders approximately 5.94 days to cover their short positions...

Continue Reading
AlphaTON and ADDRI Join Forces for Mesothelioma Clinical Research

Updated Category News Views 144

Exciting New Clinical Trial Initiative for Mesothelioma AlphaTON Capital Corp (NASDAQ: ATON) has made a significant stride in the fight against mesothelioma by partnering with Australia's Asbestos and Dust Diseases Research Institute (ADDRI). Together, they are setting the stage for an investigator-initiated clinical trial to evaluate TT-4, a promising selective A2B...

Continue Reading